Drug Profile
Ferric citrate - Akebia Therapeutics
Alternative Names: Auryxia; AVA-1014; Ferric citrate dihydrate; Ferric citrate hydrate; Fexeric; JTT-751; KRX-0502; Nephoxil; PBF-1681; Riona; Tetraferric tricitrate decahydrate; ZerenexLatest Information Update: 26 Apr 2024
Price :
$50
*
At a glance
- Originator Panacor Bioscience; Panion & BF Biotech
- Developer Akebia Therapeutics; Averoa; Japan Tobacco; Panion & BF Biotech; Torii Pharmaceutical
- Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids; Urologics
- Mechanism of Action Phosphate binding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperphosphataemia; Iron deficiency anaemia
- Preregistration Kidney disorders
Most Recent Events
- 23 Apr 2024 Preregistration for Kidney disorders in European Union (PO)
- 23 Apr 2024 Averoa expects a review of accepted MAA application under the centralised marketing authorisation procedure and a decision on a potential approval in 2025
- 31 Dec 2023 Akebia Therapeutics has patent protection for Ferric citrate in US and worldwide excluding certain Asian-Pacific countries